Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (PACTR202508592564689) titled 'A Phase 2A study of a novel antimalarial pyrrolidinamide in adult patients with uncomplicated P. falciparum malaria' on Aug. 12.
Study Type: Interventional
Study Design:
Crossover: all participants receive all interventions in different sequence during study,Non-randomised,Allocation Sequence/Code was not concealed
Primary Sponsor: GlaxoSmithKline Research And Development Limited
Condition:
Malaria
Recruitment Status: Not Recruiting
Phase: Phase-2
Date of First Enrollment: 03/02/2026
Target Sample Size: 70
Countries of Recruitment:
Gabon
Uganda
To know more, visit https://pactr.samrc.ac.za/Tri...